Solid Tumor Refractory to Conventional Treatment
2 clinical trials · Condition
◉ Watch Solid Tumor Refractory to Conventional Treatment
| Record | Firm | Date |
|---|---|---|
| Phase I Study of FXS887 in the Treatment of Solid Tumors (NCT07345637) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-01-05 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). (NCT06607692) | Fundación de investigación HM | 2024-09-20 |
Track Solid Tumor Refractory to Conventional Treatment automatically
Every clearance here is in the API, with alerts when new ones post.